CN114869931A - 鼠尾草花提取物的应用 - Google Patents
鼠尾草花提取物的应用 Download PDFInfo
- Publication number
- CN114869931A CN114869931A CN202210532300.9A CN202210532300A CN114869931A CN 114869931 A CN114869931 A CN 114869931A CN 202210532300 A CN202210532300 A CN 202210532300A CN 114869931 A CN114869931 A CN 114869931A
- Authority
- CN
- China
- Prior art keywords
- flower extract
- streptococcus mutans
- salvia
- inhibitor
- oral care
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000284 extract Substances 0.000 title claims abstract description 68
- 235000002020 sage Nutrition 0.000 title claims abstract description 45
- 241000194019 Streptococcus mutans Species 0.000 claims abstract description 48
- 239000003814 drug Substances 0.000 claims abstract description 28
- 240000007164 Salvia officinalis Species 0.000 claims abstract description 20
- 235000002912 Salvia officinalis Nutrition 0.000 claims abstract description 20
- 208000002925 dental caries Diseases 0.000 claims abstract description 18
- 239000003112 inhibitor Substances 0.000 claims abstract description 13
- 239000000463 material Substances 0.000 claims description 9
- 239000004480 active ingredient Substances 0.000 claims description 5
- 239000002324 mouth wash Substances 0.000 claims description 4
- 235000015218 chewing gum Nutrition 0.000 claims description 3
- 239000000499 gel Substances 0.000 claims description 3
- 229940051866 mouthwash Drugs 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 239000007921 spray Substances 0.000 claims description 3
- 239000000606 toothpaste Substances 0.000 claims description 3
- 229940112822 chewing gum Drugs 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 229940034610 toothpaste Drugs 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 241001072909 Salvia Species 0.000 abstract description 30
- 235000017276 Salvia Nutrition 0.000 abstract description 30
- 230000000694 effects Effects 0.000 abstract description 30
- 239000002253 acid Substances 0.000 abstract description 9
- 238000002474 experimental method Methods 0.000 abstract description 6
- 230000002401 inhibitory effect Effects 0.000 abstract description 6
- 238000004519 manufacturing process Methods 0.000 abstract description 5
- 238000000338 in vitro Methods 0.000 abstract description 4
- 101710088194 Dehydrogenase Proteins 0.000 abstract description 2
- 230000015572 biosynthetic process Effects 0.000 abstract description 2
- 229940126680 traditional chinese medicines Drugs 0.000 abstract description 2
- 230000001580 bacterial effect Effects 0.000 description 20
- 239000007788 liquid Substances 0.000 description 16
- 239000000725 suspension Substances 0.000 description 13
- 230000005764 inhibitory process Effects 0.000 description 12
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 11
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 11
- 239000000047 product Substances 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- 229940079593 drug Drugs 0.000 description 10
- 238000000034 method Methods 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 238000012360 testing method Methods 0.000 description 6
- 238000003556 assay Methods 0.000 description 5
- 239000012154 double-distilled water Substances 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 230000000844 anti-bacterial effect Effects 0.000 description 4
- 238000004737 colorimetric analysis Methods 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 229960003260 chlorhexidine Drugs 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000003235 crystal violet staining Methods 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 238000009630 liquid culture Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000012192 staining solution Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- DOUMFZQKYFQNTF-WUTVXBCWSA-N (R)-rosmarinic acid Chemical compound C([C@H](C(=O)O)OC(=O)\C=C\C=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 DOUMFZQKYFQNTF-WUTVXBCWSA-N 0.000 description 2
- IBGBGRVKPALMCQ-UHFFFAOYSA-N 3,4-dihydroxybenzaldehyde Chemical compound OC1=CC=C(C=O)C=C1O IBGBGRVKPALMCQ-UHFFFAOYSA-N 0.000 description 2
- YQUVCSBJEUQKSH-UHFFFAOYSA-N 3,4-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C(O)=C1 YQUVCSBJEUQKSH-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 241000628997 Flos Species 0.000 description 2
- 241000207923 Lamiaceae Species 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940124350 antibacterial drug Drugs 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000012452 mother liquor Substances 0.000 description 2
- QAIPRVGONGVQAS-DUXPYHPUSA-N trans-caffeic acid Chemical compound OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-DUXPYHPUSA-N 0.000 description 2
- PAFLSMZLRSPALU-MRVPVSSYSA-N (2R)-3-(3,4-dihydroxyphenyl)lactic acid Chemical compound OC(=O)[C@H](O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-MRVPVSSYSA-N 0.000 description 1
- AZOCLKLJIKZOLF-ZPOOTWMUSA-N (2r,3r)-2-[4-[(e)-3-[(1r)-1-carboxy-2-(3,4-dihydroxyphenyl)ethoxy]-3-oxoprop-1-enyl]-2-hydroxyphenoxy]-3-(3,4-dihydroxyphenyl)-3-hydroxypropanoic acid Chemical compound C([C@@H](OC(=O)/C=C/C1=CC=C(C(=C1)O)O[C@H]([C@H](O)C=1C=C(O)C(O)=CC=1)C(O)=O)C(O)=O)C1=CC=C(O)C(O)=C1 AZOCLKLJIKZOLF-ZPOOTWMUSA-N 0.000 description 1
- WCGUUGGRBIKTOS-GPOJBZKASA-N (3beta)-3-hydroxyurs-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C WCGUUGGRBIKTOS-GPOJBZKASA-N 0.000 description 1
- ACEAELOMUCBPJP-UHFFFAOYSA-N (E)-3,4,5-trihydroxycinnamic acid Natural products OC(=O)C=CC1=CC(O)=C(O)C(O)=C1 ACEAELOMUCBPJP-UHFFFAOYSA-N 0.000 description 1
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 241000722713 Carcharodon carcharias Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- PAFLSMZLRSPALU-QMMMGPOBSA-N Danshensu Natural products OC(=O)[C@@H](O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-QMMMGPOBSA-N 0.000 description 1
- 208000002064 Dental Plaque Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 238000000134 MTT assay Methods 0.000 description 1
- 231100000002 MTT assay Toxicity 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 description 1
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 description 1
- 206010031149 Osteitis Diseases 0.000 description 1
- 201000004328 Pulpitis Diseases 0.000 description 1
- 206010037464 Pulpitis dental Diseases 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- ZZAFFYPNLYCDEP-HNNXBMFYSA-N Rosmarinsaeure Natural products OC(=O)[C@H](Cc1cccc(O)c1O)OC(=O)C=Cc2ccc(O)c(O)c2 ZZAFFYPNLYCDEP-HNNXBMFYSA-N 0.000 description 1
- PAFLSMZLRSPALU-UHFFFAOYSA-N Salvianic acid A Natural products OC(=O)C(O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-UHFFFAOYSA-N 0.000 description 1
- AZOCLKLJIKZOLF-UHFFFAOYSA-N Salvianolic acid K Natural products C=1C=C(O)C(O)=CC=1C(O)C(C(O)=O)OC(C(=C1)O)=CC=C1C=CC(=O)OC(C(O)=O)CC1=CC=C(O)C(O)=C1 AZOCLKLJIKZOLF-UHFFFAOYSA-N 0.000 description 1
- 241000194025 Streptococcus oralis Species 0.000 description 1
- 239000007984 Tris EDTA buffer Substances 0.000 description 1
- 230000002053 acidogenic effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003214 anti-biofilm Effects 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 229940074360 caffeic acid Drugs 0.000 description 1
- 235000004883 caffeic acid Nutrition 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- QAIPRVGONGVQAS-UHFFFAOYSA-N cis-caffeic acid Natural products OC(=O)C=CC1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-UHFFFAOYSA-N 0.000 description 1
- 230000005757 colony formation Effects 0.000 description 1
- 238000007398 colorimetric assay Methods 0.000 description 1
- 238000005138 cryopreservation Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000005115 demineralization Methods 0.000 description 1
- 230000002328 demineralizing effect Effects 0.000 description 1
- 210000003298 dental enamel Anatomy 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229930004069 diterpene Natural products 0.000 description 1
- 125000000567 diterpene group Chemical group 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 150000002222 fluorine compounds Chemical class 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 150000002497 iodine compounds Chemical class 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 238000009629 microbiological culture Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 229940100243 oleanolic acid Drugs 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 208000004480 periapical periodontitis Diseases 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 description 1
- 229960003371 protocatechualdehyde Drugs 0.000 description 1
- 238000004080 punching Methods 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 239000013558 reference substance Substances 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- DOUMFZQKYFQNTF-MRXNPFEDSA-N rosemarinic acid Natural products C([C@H](C(=O)O)OC(=O)C=CC=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 DOUMFZQKYFQNTF-MRXNPFEDSA-N 0.000 description 1
- TVHVQJFBWRLYOD-UHFFFAOYSA-N rosmarinic acid Natural products OC(=O)C(Cc1ccc(O)c(O)c1)OC(=Cc2ccc(O)c(O)c2)C=O TVHVQJFBWRLYOD-UHFFFAOYSA-N 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 229940096998 ursolic acid Drugs 0.000 description 1
- PLSAJKYPRJGMHO-UHFFFAOYSA-N ursolic acid Natural products CC1CCC2(CCC3(C)C(C=CC4C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1C)C(=O)O PLSAJKYPRJGMHO-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Botany (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Medical Informatics (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Birds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了鼠尾草花提取物的应用,涉及中医药领域。本发明要求保护鼠尾草花提取物在制备变异链球菌的抑制剂、预防和/或治疗龋病的药物或改善龋病的口腔护理用品中的应用。本发明的实验表明鼠尾草花提取物具有变异链球菌抑制活性,可以抑制浮游状态变异链球菌的生长,抑制变异链球菌生物膜状态的形成,抑制变异链球菌胞内乳酸脱氢酶活性,以及抑制变异链球菌在体外的产酸。因此鼠尾草花提取物可用于制备变异链球菌抑制剂,以及制备预防和/或治疗龋病的药物和改善龋病的口腔护理用品。
Description
技术领域
本发明涉及中医药领域,特别是涉及鼠尾草花提取物的应用。
背景技术
龋病(dental caries)是口腔中最常见的与生物膜相关的人类传染病。是一种在细菌感染等多因素作用下导致牙体硬组织进行性破坏的疾病,如果没有及时治疗,可引发牙髓炎、根尖周炎甚至颌骨炎症等并发症。它是由很多因素之间的长期接触引起的,其中的影响因素之一牙菌斑,就是典型的细菌生物膜,由包裹在细胞外的多糖(EPS)、蛋白质和DNA中的表面附着细菌群落组成。牙齿表面的这些生物膜群落通常比它们的浮游生物对抗生素以及免疫性药物更耐受。变异链球菌(streptococcus mutans)是龋齿最重要的致病菌,定植于牙齿表面,导致牙齿结构脱钙,是牙菌斑生物膜的重要组成部分。变异链球菌代谢生物膜中的一些糖类并产生多种酸,这会进一步降低环境的pH值并导致牙釉质脱矿。而且变异链球菌是生物膜中发现的产酸最多的微生物之一,因为它可以从除任何口腔链球菌之外的发酵碳水化合物中产生酸。目前使用的化学抗生物膜剂,例如季铵盐、碘化合物和氟化物,会导致各种副作用。此外,抗菌药物的过量和长期给药会导致抗菌素耐药性,因此,在口腔领域中有很多天然药物作为新型抗菌药物的来源。
鼠尾草花(Salvia deserta Schang)为唇形科(Labiatae)鼠尾草属(Salvia)植物,一般称为新疆鼠尾草,拉丁学名为沙漠鼠尾草,系多年生植物,主产于中国新疆北部,生于田野荒地,沟边,沙滩草地及林下,海拔270-1850米。鼠尾草花的化学成分类型主要为多酚类,二萜类、三萜类、和甾体化合物等。主要化学成分有迷迭香酸,咖啡酸,熊果酸,齐墩果酸,丹参素,原儿茶醛,原儿茶酸,丹酚酸K等。新疆鼠尾草主要功效为活血止血,寒热下痢,脓血不止,跌打损伤,风湿骨痛等。迄今为止还未发现鼠尾草花关于变异链球菌的报道。
发明内容
本发明的目的是提供鼠尾草花提取物的应用,以解决上述现有技术存在的问题,本发明表明鼠尾草花提取物对变异链球菌表现出明显的抑制作用。。
为实现上述目的,本发明提供了如下方案:
本发明提供鼠尾草花提取物在制备变异链球菌的抑制剂中的应用。
本发明还提供一种变异链球菌的抑制剂,所述抑制剂的活性成分为鼠尾草花提取物。
进一步地,所述抑制剂还包括药学上可接受的辅料。
本发明还提供鼠尾草花提取物在制备预防和/或治疗龋病的药物中的应用。
本发明还提供一种预防和/或治疗龋病的药物,所述药物的活性成分为鼠尾草花提取物。
进一步地,所述药物还包括药学上可接受的辅料。
进一步地,所述药物的剂型为片剂、散剂、含潄剂、喷雾剂或凝胶剂。
本发明还提供鼠尾草花提取物在制备改善龋病的口腔护理用品中的应用。
进一步地,所述口腔护理用品为牙膏、口香糖或漱口水。
本发明还提供一种改善龋病的口腔护理用品,包括活性成分鼠尾草花提取物和口腔护理用品上可接受的辅料。
本发明的鼠尾草花提取物在变异链球菌引起的龋病方面的应用,可以将鼠尾草花提取物制成不同剂型的药物使用。具体来说,可以将鼠尾草花提取物制成包括片剂、散剂、含潄剂、喷雾剂、凝胶剂等剂型。具体的药物可包括鼠尾草花提取物和其它药学上可接受的载体,对于药物中各成分的用量可以按照药物制剂中对于成分的配比要求进行调整即可,对于鼠尾草花提取物的有效含量也可以按照不同剂型等常规的剂型要求添加,本发明并不作具体的限定。
本发明的鼠尾草花提取物在变异链球菌引起的龋病方面的应用,可以将鼠尾草花提取物直接或间接加入制备不同口腔护理用品时所需的口腔护理用品中可接受的各种常用辅料,以常规制剂方法,制成常用口腔护理用品。该口腔护理用品包括但不限于牙膏、口香糖以及漱口水。
本发明公开了以下技术效果:
本发明提供了鼠尾草花提取物的新应用,尤其是鼠尾草花提取物在制备变异链球菌抑制剂中的应用。实验表明鼠尾草花提取物具有变异链球菌抑制活性,可以抑制浮游状态变异链球菌的生长,抑制变异链球菌生物膜状态的形成,抑制变异链球菌胞内乳酸脱氢酶活性,以及抑制变异链球菌在体外的产酸。因此鼠尾草花提取物可用于制备变异链球菌抑制剂,以及制备预防和/或治疗龋病的药物和改善龋病的口腔护理用品,具有较高的应用价值和开发前景。而且鼠尾草花提取物是天然药物,可避免传统抗生素类、氟化物等产品对人体造成的副作用以及细菌耐药性。
附图说明
为了更清楚地说明本发明实施例或现有技术中的技术方案,下面将对实施例中所需要使用的附图作简单地介绍,显而易见地,下面描述中的附图仅仅是本发明的一些实施例,对于本领域普通技术人员来讲,在不付出创造性劳动的前提下,还可以根据这些附图获得其他的附图。
图1为50mg/mL(A)和25mg/mL(B)的鼠尾草花提取物对变异链球菌药敏示意图,A中,Y为阳性对照,K为阴性对照,S1-S3均为50mg/mL的鼠尾草花提取物;B中,Y为阳性对照,K为阴性对照,S4-S6均为25mg/mL的鼠尾草花提取物;
图2为鼠尾草花提取物对变异链球菌的生长曲线影响示意图;
图3为通过结晶紫实验验证的鼠尾草花提取物对变异链球菌生物膜存活率影响示意图;
图4为通过MTT实验验证的鼠尾草花提取物对变异链球菌生物膜存活率影响示意图;
图5为鼠尾草花提取物对变异链球菌胞内乳酸脱氢酶活性影响示意图;
图6为鼠尾草花提取物对变异链球菌体外产酸影响示意图。
具体实施方式
现详细说明本发明的多种示例性实施方式,该详细说明不应认为是对本发明的限制,而应理解为是对本发明的某些方面、特性和实施方案的更详细的描述。
应理解本发明中所述的术语仅仅是为描述特别的实施方式,并非用于限制本发明。另外,对于本发明中的数值范围,应理解为还具体公开了该范围的上限和下限之间的每个中间值。在任何陈述值或陈述范围内的中间值,以及任何其他陈述值或在所述范围内的中间值之间的每个较小的范围也包括在本发明内。这些较小范围的上限和下限可独立地包括或排除在范围内。
除非另有说明,否则本文使用的所有技术和科学术语具有本发明所述领域的常规技术人员通常理解的相同含义。虽然本发明仅描述了优选的方法和材料,但是在本发明的实施或测试中也可以使用与本文所述相似或等同的任何方法和材料。本说明书中提到的所有文献通过引用并入,用以公开和描述与所述文献相关的方法和/或材料。在与任何并入的文献冲突时,以本说明书的内容为准。
在不背离本发明的范围或精神的情况下,可对本发明说明书的具体实施方式做多种改进和变化,这对本领域技术人员而言是显而易见的。由本发明的说明书得到的其他实施方式对技术人员而言是显而易见得的。本发明说明书和实施例仅是示例性的。
关于本文中所使用的“包含”、“包括”、“具有”、“含有”等等,均为开放性的用语,即意指包含但不限于。
如无特殊说明,本发明实施例中所涉及的试剂均为市售产品,均可以通过商业渠道购买获得。
实验所用材料和试剂:BHI平板/液体培养基(北京索莱宝科技有限公司);复方氯己定含漱液(江苏晨牌邦德药业有限公司);MTT(德国Biofroxx公司);BCA蛋白浓度测定试剂盒(白鲨生物科技有限公司);乳酸脱氢酶比色法测试盒(武汉伊莱瑞特生物科技有限公司);培养箱(311二氧化碳培养箱,美国Thermo公司);酶标仪(SMP500,德国Spectro Max公司);pH计(pHS-3C,上海精密科学仪器有限公司雷磁仪器厂)。
实施例1鼠尾草花提取物的制备
取干燥后粉碎的鼠尾草花,按照料液质量比1:25,加入体积分数为40%的乙醇溶液,超声提取1h后过滤,将滤液冷冻干燥后,得到提取物,备用。
本发明所用鼠尾草花提取物均为本实施例制备得到的鼠尾草花提取物。需要说明的是,本实施例仅是示例性提供一种鼠尾草花提取物的制备方法,本领域技术人员在没有做出创造性劳动前提下通过现有技术获得的所有鼠尾草花的提取物均能实现本发明。
实施例2变异链球菌菌悬液的制备
取常规复苏的变异链球菌磁珠冻存管(ATCC 700610,购买于中国普通微生物菌种保藏中心)标准菌株接种于BHI液体培养基中,于37℃恒温培养箱中培养24h后,在BHI平板上划线培养24h,挑取单菌落在2mLBHI液体培养基中37℃恒温培养箱中纯培养,24h后对菌液进行倍比稀释,并涂布于平板上,培养后计数以确定菌液浓度,将其稀释至浓度为1~5×106CFU/mL的变异链球菌菌悬液,备用。
实施例3鼠尾草花提取物药敏试验
将鼠尾草花提取物用双蒸水溶解后制成终浓度为50mg/mL的母液;取母液稀释,分别得到浓度为25mg/mL和12.5mg/mL的药液。取100μL实施例2制备得到的菌悬液,均匀涂布在BHI平板中,打孔器打孔;设置多组试验,每孔内添加40μL药液,试验组药液分别为不同浓度(50、25、12.5mg/mL)的鼠尾草花提取物,阴性对照组药液为双蒸水,阳性对照组药液为复方氯己定含漱液。BHI平板放入37℃恒温培养箱中培养24h,以十字交叉法测定抑菌圈直径,每个浓度平行3个孔,求其平均值。培养结果发现不同浓度鼠尾草花提取物对变异链球菌均产生了抑菌圈,且随着提取物浓度的增大,抑菌圈直径增大,结果见表1和图1。
表1本发明鼠尾草花提取物对变异链球菌的影响
由表1可以看出,鼠尾草花提取物的浓度在12.5~50mg/mL时对浮游状态下的变异链球菌具有生长抑制作用,随着药物浓度增加作用越明显。
实施例4最小抑菌浓度(MIC)及最低杀菌浓度(MBC)测定试验
采用液体倍比稀释法,将鼠尾草花提取物用BHI液体培养基分别稀释为不同浓度梯度的样品溶液。将100μL实施例2制备的菌悬液(1~5×106CFU/mL)和不同浓度的鼠尾草花提取物溶液以1:1的比例加入96孔板中混合均匀,每个浓度3个复孔,阴性对照组为含有双蒸水的BHI菌悬液,阳性对照组为含有复方氯己定含漱液的BHI菌悬液,37℃,5%CO2培养24h后,肉眼观察无细菌生长的孔对应的药物浓度为MIC,根据MIC值测定结果,选择药液浓度大于等于MIC值的各孔分别划线于BHI平板上,37℃恒温培养24h,肉眼观察无可见菌落形成的最低浓度为最低杀菌浓度(MBC)。结果发现,鼠尾草花提取物对变异链球菌的最小抑菌浓度为14mg/mL,最低杀菌浓度为15mg/mL。可见,鼠尾草花提取物对变异链球菌具有很好的抑菌及杀菌效果。
实施例5对变异链球菌生长曲线测定试验
在96孔细胞培养板每孔中均加入100μL实施例2制备得到的菌悬液,之后再分别加入100μL的MIC(最小抑菌浓度)、1/2MIC、1/4MIC和1/8MIC浓度的鼠尾草花提取物,放入37℃恒温培养箱中培养,酶标仪波长600nm下分别测定培养0、2、4、6、8、12、24、36h后的OD值,以未加鼠尾草花提取物的孔为对照组,为避免药液本身颜色的影响,取不同时段OD600的差值,实验重复3次,计算ΔOD600均值,绘制细菌的生长曲线图。生长曲线如图2所示,相对于对照组,培养6小时以后不同浓度鼠尾草花提取物均对变异链球菌的生长具有显著抑制作用。
实施例6对变异链球菌生物膜生长活性影响试验
采用结晶紫染色法和MTT比色法检测对变异链球菌细菌生物膜生长活性的影响。在96孔细胞培养板每孔中加入100μL的菌悬液和相同体积的药液(浓度为4MIC、2MIC、MIC、1/2MIC或1/4MIC),每个浓度重复3个孔,含有双蒸水的菌悬液作为对照,然后置于培养箱中37℃恒温培养24h后取出96孔板,对于结晶紫实验,去除96孔中的培养基,用PBS润洗2次后干燥,每孔分别加入200μL 0.1%的结晶紫染色液对形成的生物膜染色15min。多余未结合的结晶紫染色液用无菌PBS缓冲液冲洗去除,待干燥后各孔分别加入200μL 95%乙醇溶液,以洗脱与生物膜结合的结晶紫,静置后于酶标仪分别检测600nm处各孔的OD值;对于MTT实验,去除孔中的培养基,用PBS润洗2次后向孔中加入100μL,5mg/mL的MTT染液。37℃避光染色3h,小心吸除上清液后,在室温加入200μLDMSO溶解染液10min后在590nm下测定OD值。按照以下方式计算抑制率。
抑制率计算公式为:抑制率=(1-OD实验组/OD对照组)*100%;
生物膜存活率=100%-抑制率。
试验结果如图3和图4所示,无论是结晶紫实验还是MTT比色法,实验组与对照组相比,鼠尾草花提取物对生物膜的抑制作用显著(*P<0.05),且随着提取物浓度的升高,生物膜的存活率降低。可见,鼠尾草花提取物对变异链球菌生物膜的生长存在明显抑制作用。
实施例7对乳酸脱氢酶(LDH)活性的影响的试验
将4mL实施例2制备的菌悬液分别与用实施例1制备的提取物加双蒸水配制成的系列药液(MIC、1/2MIC、1/4MIC和1/8MIC)按1:1(v/v)混合,以不含药液的菌悬液作为对照组,每个浓度重复三次,培养24h。取出后3000r/min,离心5min后吸弃上清液,收集菌体沉淀,用PBS轻柔洗涤两次后向其中加入1mL含5mg/mL的溶菌酶的TE缓冲液,振荡器振动混合均匀后放置在培养箱37℃孵育1h后,3000r/min离心10min后,收集上清液放在4℃备用。
使用BCA法测定细菌的蛋白质,测定流程按照试剂盒说明操作,操作表如表2所示,以牛血清白蛋白(BSA)含量为横坐标,以A562为纵坐标,绘制标准曲线,计算样品中的蛋白质浓度。
表2 BCA法测定变异链球菌蛋白质操作表
采用乳酸脱氢酶比色法测试盒测定LDH活性,试剂盒具体测定步骤按照表3所示。LDH活力(U/gprot)=(ΔA450-b)×f×1000*/(a×Cpr),定义为每克组织蛋白37℃与基质作用15min,在反应体系中产生1μmol丙酮酸为1个LDH活力单位(U)。(注:ΔA450:测定孔OD值-对照品OD值;a:标曲的斜率;b:标曲的截距;f:待测样品加入检测体系之前的稀释倍数;Cpr:待测样本的蛋白质浓度(gprot/L);1000*:1L=1000mL。)
表3 LDH比色法测定变异链球菌胞内LDH活性操作表
实验结果如图5所示,与对照组相比,鼠尾草花提取物浓度在14mg/mL-3.5mg/mL范围内,对细菌胞内乳酸脱氢酶活性均有明显的抑制作用,且抑制作用呈浓度依赖性。
实施例8对变异链球菌体外产酸影响的试验
采用pH计测定鼠尾草花提取物对变异链球菌的产酸能力的影响,将4mL实施例2制备的菌悬液3000r/min,离心5min后弃上清,用PBS轻柔洗涤两次后,菌体沉淀用4mL缓冲液(含50mmol/L氯化钾,1mmol/L的氯化镁,1%w/v的葡萄糖)重悬,设置含浓度为4MIC、2MIC、MIC、1/2MIC、1/4MIC的鼠尾草花提取物的缓冲液为实验组,以不含药液的缓冲液为对照组。用pH计监测3h内每0.5h各组溶液体系pH值的变化。实验结果显示,各实验组的终产酸量与对照组相比均有统计学差异(P<0.5),高浓度组明显能抑制3h最终的产酸量,且各实验组呈现剂量依赖效应。
以上所述的实施例仅是对本发明的优选方式进行描述,并非对本发明的范围进行限定,在不脱离本发明设计精神的前提下,本领域普通技术人员对本发明的技术方案做出的各种变形和改进,均应落入本发明权利要求书确定的保护范围内。
Claims (10)
1.鼠尾草花提取物在制备变异链球菌的抑制剂中的应用。
2.一种变异链球菌的抑制剂,其特征在于,所述抑制剂的活性成分为鼠尾草花提取物。
3.根据权利要求2所述的抑制剂,其特征在于,所述抑制剂还包括药学上可接受的辅料。
4.鼠尾草花提取物在制备预防和/或治疗龋病的药物中的应用。
5.一种预防和/或治疗龋病的药物,其特征在于,所述药物的活性成分为鼠尾草花提取物。
6.根据权利要求5所述的药物,其特征在于,所述药物还包括药学上可接受的辅料。
7.根据权利要求6所述的药物,其特征在于,所述药物的剂型为片剂、散剂、含潄剂、喷雾剂或凝胶剂。
8.鼠尾草花提取物在制备改善龋病的口腔护理用品中的应用。
9.根据权利要求8所述的应用,其特征在于,所述口腔护理用品为牙膏、口香糖或漱口水。
10.一种改善龋病的口腔护理用品,其特征在于,包括活性成分鼠尾草花提取物和口腔护理用品上可接受的辅料。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210532300.9A CN114869931A (zh) | 2022-05-09 | 2022-05-09 | 鼠尾草花提取物的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210532300.9A CN114869931A (zh) | 2022-05-09 | 2022-05-09 | 鼠尾草花提取物的应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN114869931A true CN114869931A (zh) | 2022-08-09 |
Family
ID=82676305
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210532300.9A Pending CN114869931A (zh) | 2022-05-09 | 2022-05-09 | 鼠尾草花提取物的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114869931A (zh) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1117712A (zh) * | 1993-02-10 | 1996-02-28 | 伊塞哈根药材经营股份有限公司 | 鼠尾草花的提取物及其提取方法和用途 |
CN1225576A (zh) * | 1997-04-04 | 1999-08-11 | 奥普蒂瓦公司 | 用于口腔卫生产品的抗微生物制剂 |
CN1254555A (zh) * | 1998-11-19 | 2000-05-31 | 药厂伊森哈根有限公司 | 鼠尾草提取物在制备除臭剂中的应用 |
-
2022
- 2022-05-09 CN CN202210532300.9A patent/CN114869931A/zh active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1117712A (zh) * | 1993-02-10 | 1996-02-28 | 伊塞哈根药材经营股份有限公司 | 鼠尾草花的提取物及其提取方法和用途 |
CN1225576A (zh) * | 1997-04-04 | 1999-08-11 | 奥普蒂瓦公司 | 用于口腔卫生产品的抗微生物制剂 |
CN1254555A (zh) * | 1998-11-19 | 2000-05-31 | 药厂伊森哈根有限公司 | 鼠尾草提取物在制备除臭剂中的应用 |
Non-Patent Citations (5)
Title |
---|
DE OLIVEIRA ET AL: "Antimicrobial activity of noncytotoxic concentrations of Salvia officinalis extract against bacterial and fungal species from the oral cavity", 《GENERAL DENTISTRY》 * |
HAMID KERMANSHAH ET AL: "The Effect of Hydro Alcoholic Extract of Seven Plants on Cariogenic Bacteria-An in Vitro Evaluation", 《ORAL HEALTH AND DENTAL MANAGEMENT》 * |
WINSKA K ET AL: "Essential Oils as Antimicrobial Agents—Myth or Real Alternative?", 《MOLECULES》 * |
李强等: "药用鼠尾草花的化学成分研究", 《中医药学报》 * |
郑娟等: "天然原料在牙膏中的应用及全天然牙膏的开发", 《口腔护理用品工业》 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Hu et al. | Nanoparticles for the treatment of oral biofilms: current state, mechanisms, influencing factors, and prospects | |
Gulube et al. | Effect of Punica granatum on the virulence factors of cariogenic bacteria Streptococcus mutans | |
Achmad et al. | Effectiveness of chitosan tooth paste from white shrimp (Litopenaeusvannamei) to reduce number of Streptococcus mutans in the case of early childhood caries | |
Aljamali et al. | Microbial Studying of (Thiazole, Oxadiazole, Thiadiazole)–Derivatives on Mouth and Teeth Bacteria | |
Sari et al. | Antibacterial and antifungal effectiveness of virgin coconut oil (VCO) mousse against Streptococcus mutans and candida albicans biofilms | |
Rai et al. | Comparison of antimicrobial efficacy of four different plant extracts against cariogenic bacteria: an in vitro study | |
Ahmed et al. | Comparative Evaluation of Antimicrobial Efficacy of Herbal Formulations of Septilin and Triphala with Conventional 2% Chlorhexidine on Root Canal and Oral Commensal Bacteria using Kirby Bauer Method: An: in-vitro: Study | |
CN114869931A (zh) | 鼠尾草花提取物的应用 | |
Buzia¹ et al. | Antibacterial action of certain tretinoin and benzoyl peroxide liposomes. Case study | |
CN114099413A (zh) | 一种益生菌与茶多酚复配的组合物、制剂及其应用 | |
Muhsinin et al. | Formulation and Evaluation of a Turmeric Kombucha Facial Toner with Potential as an Anti-Acne Agent | |
Helalat et al. | The effect of curcumin on growth and adherence of major microorganisms causing tooth decay | |
Marques et al. | Hyaluronic acid-based gels for oral application: Comparison of in vitro effects on gingival cells and bacteria | |
Singh et al. | In vitro antipyrial activity of psidium guajava leaf extract | |
CN115894286B (zh) | 一种小分子多胺类抗菌纳米材料及其制备方法和应用 | |
Rodrigues et al. | Evaluation and Comparison of Antimicrobial Effects of Chlorhexidine (CHX) and Chitosan (CHT) Mouthwash in Chronic Periodontitis (CGP) Patients-A Clinico-microbiological Study. | |
Yuanita et al. | Inhibitory effect of nano Stolephorus insularis and calcium hydroxide on glucosyltransferase (GTF) activity of Lactobacillus aciophilus | |
Rastegar | Evaluation of Antimicrobial Effect of Licorice Extract Against Oral Microorganisms | |
Guru et al. | Comparative Evaluation of the Effect of Propolis and Chlorhexidine Mouthwashes on Streptococcus mutans Counts in Saliva: An In Vivo Study | |
Linggriani et al. | Differences in the effects of 0.05% and 0.1% propolis flavonoids on in vitro biofilm formation by streptococcus mutans from children’s dental plaque | |
Tweij-Thu-Alfeqar et al. | Comparative study between pre and post bacterial growth of periodontal infections by treatment with extracts Rue. An in vitro study | |
TW201330858A (zh) | 用於抑制或殺除牙齦卟啉單胞菌之組成物及其用於減輕或治療牙周病及其他疾病之應用 | |
Raju et al. | An in vitro evaluation of antimicrobial activity of Drosera peltata JE Sm against clinically isolated human periodontal pathogens Int | |
Singh | Evaluation Of Efficacy Of Chicorium Intybus Extract On Periodontal Pathogens: An In-Vitro | |
Nouri et al. | EVALUATION OF STEVIA REBAUDIANA EFFECT ON LACTOBACILLUS PLANTARUM GROWTH: AN IN VITRO STUDY |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20220809 |